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To determine the initiation strategy of the hepatitis E virus (HEV) open reading frame 3 (ORF3), we
constructed five HEV mutants with desired mutations in the ORF1 and ORF2 junction region and tested
their levels of in vivo infectivity in pigs. A mutant with a C-terminally truncated ORF3 is noninfectious in
pigs, indicating that an intact ORF3 is required for in vivo infectivity. Mutations with substitutions in the
first in-frame AUG in the junction region or with the same T insertion at the corresponding position of
HEV genotype 4 did not affect the virus infectivity or rescue, although mutations with combinations of the
two affected virus recovery efficiency, and a single mutation at the third in-frame AUG completely
abolished virus infectivity in vivo, indicating that the third in-frame AUG in the junction region is
required for virus infection and is likely the authentic initiation site for ORF3. A conserved double
stem-loop RNA structure, which may be important for HEV replication, was identified in the junction
region. This represents the first report of using a unique homologous pig model system to study the
molecular mechanism of HEV replication and to systematically and definitively identify the authentic
ORF3 initiation site.
Hepatitis E virus (HEV) is an important human pathogen
responsible for enterically transmitted acute hepatitis in many
regions of the world. A unique feature associated with HEV
infection is the relatively high mortality rate in infected preg-
nant women, which can reach up to 28% (11). In developing
countries where sanitation conditions are poor, the disease is
transmitted via the fecal-oral route through virus-contami-
nated water or food (19). In industrialized countries, immuno-
globulin G (IgG) anti-HEV antibodies have been detected in a
significant proportion of healthy individuals; however, only
sporadic cases of acute hepatitis E have been reported. In-
creasing evidence indicates that hepatitis E is a zoonotic dis-
ease, and animal reservoirs for HEV exist (17, 19, 22, 24, 31).
We recently discovered and characterized two animal strains of
HEV that are genetically and antigenically closely related to
human HEV: swine HEV from pigs (15–16) and avian HEV
from chickens (1, 7–8). We subsequently demonstrated that
swine HEV can cross species barriers and infect nonhuman
primates (16) and that pig handlers in the United States and
other countries are at increased risk of zoonotic HEV infection
(18). All swine HEV isolates thus far identified from pigs
belong to either genotype 3 or genotype 4 and in many cases
are genetically indistinguishable from human HEV genotypes
3 and 4 (19, 20, 31). Swine HEV infection in specific-pathogen-
free pigs provided us a unique animal model to study HEV
replication and pathogenesis (6, 10).
HEV is currently classified in the sole genus Hepevirus of the
family Hepeviridae (2). The virus is a single-stranded, positive-
sense, polyadenylated RNA molecule of approximately 7.2 kb
in size with short 5 and 3 noncoding regions. The viral ge-
nome contains three open reading frames (ORFs). ORF1 at
the 5 end encodes nonstructural proteins that are involved in
virus replication and viral protein processing. ORF2 at the 3
end encodes a 660-amino-acid capsid protein. The AUG start
codon of ORF3 was predicted to overlap with the UGA stop
codon of ORF1, thus encoding a small protein of 123 amino
acid residues. ORF3 also overlaps with ORF2 at its 3 end
since ORF2 begins 38 nucleotides (nt) downstream of ORF1
(19, 23).
At least four major genotypes of HEV have been identified
in mammalian species (8–9, 21). The genomic organization
among HEV genotypes 1, 2, and 3 is conserved (Fig. 1A).
However, the T1 strain of the prototype HEV genotype 4 has
a unique genomic organization due to a frameshift mutation
caused by a single nucleotide insertion (Fig. 1A) (30): ORF3
does not overlap with ORF1 and starts 28 bases downstream of
ORF1, whereas ORF2 utilizes the AUG start codon, overlap-
ping ORF1 as its putative initiation site, and thus extends 14
amino acids at the 5 end. Sequence analyses of additional
HEV genotype 4 isolates showed that they all have similar
types of genomic organization, with only 114 amino acid resi-
dues in the predicted ORF3 protein (19, 21). The genomic
organization of the recently identified avian HEV (putative
genotype 5) is quite different from those of the four mamma-
lian HEV genotypes: ORF3 also overlaps ORF2, but neither
ORF3 nor ORF2 overlaps ORF1 (8–9) (Fig. 1B).
The function of ORF3 protein is unknown, but recent stud-
ies based upon genotype 1 HEV suggested that it may be
involved in HEV virion morphogenesis and viral pathogenesis
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(25–26). It has been reported that recombinant ORF3 protein
forms dimers through amino acid residues 81 to 123 (28);
interacts with ORF2 protein mediated by amino acid residues
57 to 81 (23); binds various SH3 domain-containing proteins
via amino acid residues 75 to 113 and activates mitogen-acti-
vated protein kinase (12); and interacts with a liver-specific
protein, 1-microglobulin/bikunin precursor (AMBP), and its
two processed proteins, 1m (26) and bikunin (27), through
the C-terminal region (amino acid residues 81 to 123). These
data indicated that the C-terminal region of the HEV ORF3
protein is a multifunctional domain.
We recently developed a reverse genetics system for geno-
type 3 HEV using pigs as a model (10). To demonstrate the
utility of this unique system, which bypasses the traditional cell
culture system that is inefficient for HEV (3), for studying the
molecular mechanism of HEV replication and to determine
the function of the ORF3 protein in viral replication and
pathogenesis in vivo, in this study we utilized the newly devel-
oped genotype 3 HEV reverse genetics system and the unique
pig model to identify the authentic initiation site of the HEV
ORF3 protein.
Predicted initiation site of HEV ORF3 protein based upon
sequence analyses. It has been a common assumption in the
HEV scientific community that the ORF3 start codon overlaps
the ORF1 stop codon in HEV genotypes 1 through 3 and that
the ORF2 start codon begins 35 (genotype 3) or 38 bases
(genotypes 1 and 2) downstream from ORF1. The recent dis-
coveries of HEV genotype 4 and the avian HEV (putative
genotype 5) with different predicted ORF2 and ORF3 initia-
tion codons as well as the recent finding that the functional
domains of the ORF3 protein are all located in the C-
terminal region led us to question whether the common
assumptions are correct.
For convenience, in this study, the region between the ORF1
stop codon and the putative ORF2 initiation codon that con-
tains the presumed N terminus of ORF3 was designated the
“junction region.” Sequence analyses of the junction regions
from the four recognized HEV genotypes revealed the exis-
FIG. 1. Schematic diagram of the predicted genomic organization and nucleotide sequence alignment of the noncoding junction region between
ORF1 and ORF2 of HEV. (A) Swine HEV (genotype 3), Sar-55 strain (genotype 1), Mexico strain (genotype 2), and T1 strain (genotype 4).
Nucleotide position numbers correspond to the sequence of clone pSHEV-3 of genotype 3 swine HEV. Dots denote sequence identity, and dashes
denote deletions. The stop codon of ORF1 is indicated by carets, and the four AUGs are indicated by asterisks. AUG1, -2, and -3 are in-frame
and serve as the potential ORF3 start codons, and AUG4 serves as the ORF2 start codon among HEV genotypes 1 to 3. In genotype 4, a
single-nucleotide T insertion 2 nt downstream of AUG2 (marked with circle) results in the predicted ORF3 initiation at AUG3 and the predicted
ORF2 initiation at AUG1, -2, and/or -4. The presumed coding regions between AUG1 and AUG3 for ORF3 in HEV genotypes 1 to 3 and between
AUG1 and AUG4 for ORF2 in genotype 4 HEV are denoted by the dashed-line box based on our hypothesis that AUG3 is the authentic ORF3
initiation site and that AUG4 is the authentic ORF2 initiation site for all HEV genotypes. (B) Avian HEV (putative genotype 5). There exist three
AUGs that could potentially serve as the initiation sites for different ORFs. In addition to AUG2 and AUG3 as the potential ORF3 and ORF2
start codons, respectively, a novel small ORF X is predicted to start at AUG1.
VOL. 81, 2007 NOTES 3019
tence of three in-frame AUGs in all genotype 1 through 3
HEVs, designated AUG1, -2, and -3, from 5 to 3 ends, which
could each potentially serve as the ORF3 start codon (Fig. 1A).
The first AUG (AUG1) overlapping the ORF1 stop codon
is the current presumptive ORF3 initiation site, while AUG4 is
the start codon for ORF2. Since there is a single-nucleotide T
insertion between AUG2 and AUG3 in HEV genotype 4,
AUG1 and AUG2 in HEV genotypes 1 through 3 could not be
used as alternative ORF3 initiation sites. Consequently, the
ORF3 initiation site for HEV genotype 4 is predicted to start
at only AUG3 but the ORF2 could potentially start at AUG1,
-2, or -4 (Fig. 1A).
One of the critical factors affecting translation initiation and
efficiency is the context of the AUG start codon sequence (13).
The Kozak consensus sequence, GCCGCC(A/G)CCAUGG
(underlining indicates the start codon), is the optimal se-
quence, where the 3 and 4 nucleotides are important for
controlling initiation efficiency. Sequence analyses of the junc-
tion region revealed that the context of AUG3 in HEV geno-
types 1 through 4 is more consistent with the Kozak sequence
(Fig. 1A). In addition, AUG3 exists at the same position in all
four genotypes of mammalian HEV; it exists as well in avian
HEV but at a different position. We thus hypothesize that all
genotypes of HEV utilize AUG3 instead of the current com-
monly presumed AUG1 for the ORF3 initiation and that HEV
genotype 4 utilizes the same ORF2 start codon as do HEV
genotypes 1 through 3. Therefore, the AUG1 overlapping the
ORF1 stop codon is neither the presumed ORF3 initiation site
for HEV genotypes 1 through 3 nor the predicted ORF2 ini-
tiation site for genotype 4 HEV. We believe that all HEVs,
including avian HEV, have the same genomic organization in
that ORF3 overlaps with ORF2, but neither ORF2 nor ORF3
overlaps with ORF1.
The hypothesized ORF2 and ORF3 initiation codons for
HEV are based upon sequence analyses and computer predic-
tions. Recently, Graff et al. (5) identified a bicistronic, sub-
genomic mRNA of human HEV genotype 1 from which both
ORF2 and ORF3 were translated using an in vitro HEV rep-
licon system. The start site of this subgenomic RNA lies be-
tween AUG2 and AUG3, and thus, it is deduced that AUG3 is
the site for ORF3 translation (5). However, with the lack of an
efficient cell culture system for HEV (3), the results obtained
from an artificial in vitro HEV replicon system (in which viral
replication is not in the context of complete viral genome) may
not reflect what really happens in vivo. Importantly, major
differences in HEV replication and pathogenesis have been
reported among different HEV genotypes: levels of replication
of genotypes 1 and 2 are restricted in humans, whereas HEV
genotypes 3 and 4 infect both humans and pigs (and possibly
other animal species). Therefore, it is important to define the
role of ORF3 protein in HEV replication in a homologous
animal model system using a different HEV genotype with a
broader host tropism. In this study, we take advantage of the
HEV genotype 3 reverse genetics system and the unique ho-
mologous swine model system (pigs are the natural host of
genotype 3 swine HEV) we recently developed to systemati-
cally delineate the roles of the three in-frame AUGs of the
junction region in ORF3 initiation in vivo and to evaluate the
utility of this unique homologous pig model system for study-
ing the molecular mechanism of HEV replication.
Construction of HEV mutants and determination of their
levels of in vivo infectivity in pigs. The construction and char-
acterization of an infectious cDNA clone of genotype 3 swine
HEV, pSHEV-3, has been previously described (10). In this
study, pSHEV-3 was used as the parental genomic template for
the construction of HEV mutants. The pSHEV-3 infectious
cDNA clone contains two unique AflII and AvrII restriction
enzyme sites, located outside the junction region, that were
used to facilitate the cloning steps in this study. By using
standard recombinant DNA techniques, we introduced muta-
tions into various mutants by PCR-directed mutagenesis with
a sense primer (5-GTCTCTTAAGGGTTTCTGGAAGAAG
C-3) containing an AflII site (underlined) and reverse primers
containing the respective desired mutation (Fig. 2A) as well as
an AvrII site. Pfu Ultra high-fidelity DNA polymerase (Strat-
agene) was used in PCR amplification to minimize unwanted
mutations. Each amplified PCR fragment was digested with
the two restriction enzymes and subsequently replaced the
corresponding region in the pSHEV-3 clone to produce re-
spective mutants (Fig. 2A). Five HEV mutants, designated
mutant-AGA, mutant-1, mutant-3, mutant-5, and mutant-19,
were constructed. The full-length genome of each mutant was
sequenced to verify the introduced mutations.
To generate RNA transcripts for the in vivo infectivity study
of the mutants, the pSHEV-3 wild-type infectious cDNA clone
and the five mutant clones were each linearized with XbaI. In
vitro transcriptions of capped RNA were performed for each
construct at 37°C in a 750-l reaction mixture containing ap-
proximately 43 g of each linearized plasmid DNA, 75 l of
10 reaction buffer, 375 l of 2 nucleoside triphosphate-
CAP analog, 75 l of enzyme mix, and an additional 37.5 l of
a 30 mM GTP stock for capping (mMessage mMachine T7
transcription kit; Ambion). The RNA transcripts were ana-
lyzed by electrophoresis of 5 l of the reaction mixture in a 1%
agarose gel. A strong RNA band of expected size was observed
for each construct, and the yields from each construct were
similar (Fig. 2B). The remaining RNA reaction mixture from
each construct was diluted with 2.25 ml of cold RNase-,
DNase-, and proteinase-free phosphate-buffered saline (PBS)
buffer, aliquoted in three vials of 1 ml each, and immediately
frozen on dry ice until used for the intrahepatic inoculation of
pigs.
We previously developed an in vivo transfection system to
bypass the cell culture system, which is inefficient for HEV (3),
for testing the infectivity of the swine HEV infectious clone
and its derivatives in pigs (10). The procedure we used to
determine the infectivity of the five HEV mutants in this study
is essentially the same as that we previously reported (10).
Briefly, 3-week-old, specific-pathogen-free piglets (n  21)
that were seronegative for HEV were randomly assigned into
seven groups of three pigs each (groups A to G). Each group
of pigs was housed separately and maintained under conditions
meeting ICAUC requirements. The capped RNA transcript
inocula from each mutant as well as the wild-type swine HEV
infectious cDNA clone were intrahepatically injected into the
liver of each piglet via the ultrasound-guided intrahepatic in-
oculation technique (10). The three group A pigs (identifica-
tion [ID] numbers 63, 107, and 115) were each injected with 1
ml of the RNA transcripts from the wild-type pSHEV-3 clone
as positive controls. Group B pigs (ID numbers 19, 67, and
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120) were each injected with 1 ml of PBS buffer as negative
controls. Pigs in groups C (ID numbers 53, 108, and 110), D
(ID numbers 59, 109, and 117), E (ID numbers 60, 70, and 72),
F (ID numbers 30, 106, and 113), and G (ID numbers 37, 103,
and 118) were each similarly injected with capped RNA tran-
scripts from mutant-AGA, mutant-1, mutant-3, mutant-5, and
mutant-19, respectively (Fig. 2A). Pigs in all groups were mon-
itored daily for clinical signs of disease for a total of 10 weeks.
Fecal and serum samples from each pig were collected prior to
inoculation. Fecal samples were collected every 3 days postin-
oculation, and serum samples were collected every 6 days
postinoculation. None of the pigs had clinical signs of hepatitis
during the course of the study, which is consistent with the
results of our previous study (6, 10). Fecal and serum samples
were tested for the presence of swine HEV RNA by a nested
reverse transcription-PCR (RT-PCR) as described previously
(10), and serum samples were also tested by an enzyme-linked
immunosorbent assay (ELISA) for IgG anti-HEV antibodies
(6, 15–16).
Pig 115 in group A died 1 day after inoculation, likely from
the inoculation procedure. The remaining two pigs in group A
seroconverted to IgG anti-HEV antibodies at 30 (pig 63) and
42 (pig 107) days postinfection (dpi) (Fig. 3A), whereas the
three pigs in group B remained seronegative throughout the
study (Fig. 3B). Since the ELISA to detect HEV antibodies
was based on a recombinant HEV capsid ORF2 protein, se-
roconversion to anti-ORF2 antibody implies that the ORF2
protein was produced in vivo in group A pigs. Both of the
remaining pigs in group A shed virus in feces in a pattern
consistent with that associated with the wild-type swine HEV
infectious cDNA clone (10) (Fig. 3A). Viremia was also de-
tected variably in the two group A positive control pigs (Fig.
3A). As expected, viremia and fecal virus shedding were not
detected in the three group B negative control pigs.
Expression of an intact ORF3 is required for in vivo HEV
infectivity. The HEV genotype 3 mutant-AGA was designed to
test whether the expression of an intact ORF3 is required for
viral infectivity in vivo. Since both triplets CGC and AGA
encode arginine, the second codon of ORF2 was silently mu-
tated from CGC to AGA to introduce a TGA stop codon in the
ORF3 leading to the C-terminal truncation of ORF3 (Fig. 2A).
In this mutant-AGA, the authentic capsid protein encoded by
the ORF2 gene remains unchanged. The three pigs in group
C that were intrahepatically inoculated with capped RNA
transcripts from the mutant-AGA had no evidence of sero-
conversion, fecal virus shedding, or viremia throughout the
experiment (Fig. 3C), indicating the lack of infectivity for the
mutant-AGA. Under the in vivo experimental conditions, it is
FIG. 2. Construction of HEV mutants derived from the wild-type genotype 3 swine HEV consensus cDNA clone pSHEV-3. (A) Alignment of
nucleotide sequences in the junction regions among the mutants and their group assignments for the in vivo infectivity study in pigs. T7p represents
a T7 RNA polymerase core promoter, and A15 represents a 15-nt poly(A) tail. The unique AflII and AvrII restriction sites on pSHEV-3 used for
the cloning purpose are also shown. For an explanation of the symbols, see the legend for Fig. 1, panel A. (B) In vitro transcription of full-length
capped RNAs from the wild-type infectious cDNA clone pSHEV-3 and five HEV mutant clones. Five microliters of the transcription mixture was
separated in a 1% agarose gel to check the quality of the transcription before being intrahepatically inoculated into the liver of pigs. An arrow
indicates the in vitro RNA transcripts of expected size.
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difficult to directly detect whether ORF2 capsid protein was
synthesized in infected porcine cells. However, since the re-
combinant ORF2-derived polypeptide was used as the antigen
in the ELISA to detect the production of anti-ORF2 antibody
from the sera of inoculated pigs, it is reasonable to assume that
the seronegative results imply the lack of ORF2 protein pro-
duction due to lack of infection. A genotype 1 HEV mutant
with an introduced stop codon (ORF3-null mutant) derived
from the Sar-55 strain of human HEV was noninfectious in
rhesus macaques (4); however, the ORF3-null mutant was able
to synthesize ORF2 protein in the absence of ORF3 in cul-
tured Huh-7 cells, suggesting that the deficiency of ORF3
expression resulted in the loss of infectivity for the mutant (4).
Therefore, it is reasonable to believe that the failure to recover
the HEV genotype 3 mutant-AGA in inoculated pigs was due
to the deficiency of ORF3 protein expression. Since the intact
ORF3 expression is required for HEV in vivo infectivity, one
of the three in-frame AUGs of ORF3 in the junction region
must be utilized for translation initiation.
Initiation at AUG1 of ORF3 is not required for viral infec-
tivity. HEV mutant-1 was constructed with a single point mu-
tation at nt 5150, from A to C, which knocked out AUG1 of
ORF3 (Fig. 2A). The introduced mutation is a structurally
conserved substitution for ORF1, from glutamic acid (GAA)
to aspartic acid (GAC). Mutant-1 was designed to test whether
AUG1 serves as the initiation codon of ORF3. All three group
D pigs inoculated with the capped RNA transcripts from mu-
tant-1 had fecal virus shedding and viremia (Fig. 3D). Pigs 59,
109, and 117 all seroconverted to IgG anti-HEV antibodies at
36, 54, and 30 dpi, respectively. To determine whether the
introduced mutation was retained in the virus recovered from
pigs, we amplified and sequenced a genomic fragment contain-
ing the junction region by using a sense primer (5-CAGCGA
AGGGGTTGGTTGGATG-3) and a reverse primer (5-CA
GCGAAGGGGTTGGTTGGATG-3) from selected fecal
samples of the three group D pigs. Sequence analyses showed
that the sequences recovered from the three pigs all retained
the introduced mutation C at nt 5150, indicating that the in-
fectious virus originated from mutant-1. The results indicated
that AUG1 of ORF3 is not required for viral infectivity in vivo
and is likely not utilized as the ORF3 initiation codon.
Initiation at AUG2 of ORF3 is not required for viral infec-
tivity in vivo. To test whether the AUG2 is required for viral
infectivity, a single-nucleotide T insertion downstream from
AUG2 was introduced into the pSHEV-3 clone of HEV ge-
notype 3 (at the same position as that of HEV genotype 4) to
produce mutant-3 (Fig. 2A). Mutant-3 would abolish the po-
tential function of AUG2 and mimic the AUG1 and AUG2
frameshift mutants in the junction region of HEV genotype 4.
All three group E pigs inoculated with capped RNA transcripts
from mutant-3 seroconverted to IgG anti-HEV antibodies
(Fig. 3E). Fecal virus shedding was detected in the samples
from pig 60 at 18 and 21 dpi as well as in samples from pig 70
at 39, 51, and 54 dpi. Pig 72 also had detectable viremia at 24
and 30 dpi. A similar construct with a T insertion in the back-
bone of a genotype 1 human HEV strain was shown to be
infectious in vitro and produced both ORF2 and ORF3 pro-
teins (5), which is consistent with our finding in this study with
the T insertion mutant of the genotype 3 swine HEV.
HEV mutant-5 was constructed to further verify the results
obtained from mutant-1 and mutant-3, in which the single
point mutation at AUG1 and the single-nucleotide T insertion
downstream from AUG2 were introduced simultaneously,
leading to a double mutant (Fig. 2A). Mutant-5 was intended
not only to verify the dispensable nature of AUG1 and AUG2
as the initiation sites of ORF3 for viral infectivity for HEV
genotypes 1 to 3 but also to determine whether AUG1 is used
as the ORF2 initiation codon for HEV genotype 4. Of the
three group F pigs inoculated with the RNA transcripts from
mutant-5, only pig 106 had fecal virus shedding, viremia, and
seroconversion; pigs 30 and 113 did not show any of the three
markers (Fig. 3F), suggesting that the recovery of mutant-5 was
less efficient than those of mutant-1 and mutant-3.
The junction region was amplified by RT-PCR from selected
fecal samples of pig 72 in group E and pig 106 in group F and
subsequently sequenced. The nucleotide T insertion was re-
tained in the recovered viruses from pig 72, and the double
mutations were also retained in the recovered viruses from pig
106. Additional mutations were not identified in this region.
Taken together from the results with mutant-3 and -5, we
showed that AUG1 and AUG2 are not necessary for viral
infectivity in vivo and thus provide indirect evidence that the
third in-frame AUG (AUG3) is the authentic initiation site for
all four genotypes of HEV. The results with mutant-5 also
indicated that the common presumption of AUG1 as the ini-
tiation codon of ORF2 for genotype 4 HEV is likely incorrect.
Initiation at AUG3 of the ORF3 is required for viral infec-
tivity. The AUG3 of the ORF3 was changed to a leucine
(CUG) by a point mutation from A to C to produce the HEV
genotype 3 mutant-19 (Fig. 2A). The three group G pigs inoc-
ulated with the capped RNA transcripts from mutant-19 had
no viremia, fecal virus shedding, or seroconversion throughout
the experiment (Fig. 3G), indicating a lack of viral infectivity as
we expected. Based upon the results from mutant-AGA and
mutant-19, it is likely that the failure to recover mutant-19 was
due to the ORF3 expression deficiency. Since AUG1 and
AUG2 remain unchanged in mutant-19, we thus conclude that
the AUG3 plays a key role in the ORF3 translation initiation
which is essential for viral infectivity in vivo and that AUG3 is
the authentic initiation site of ORF3 not only in HEV geno-
type 4, but also in HEV genotypes 1 to 3. Most recently, Graff
et al. (5) reported that human HEV genotype 1 mutant
pHEV5131Ala, in which AUG3 was mutated to GCA, did not
produce ORF3 protein in the presence of ORF2 synthesis in
FIG. 3. Determination of the in vivo infectivity of wild-type and mutant cDNA clones of genotype 3 HEV in pigs. Fecal viral shedding, viremia,
and seroconversion to IgG anti-HEV antibodies in pigs intrahepatically inoculated with capped RNA transcripts from wild-type swine HEV clone
pSHEV-3 (A), PBS buffer (B), mutant-AGA (C), mutant-1 (D), mutant-3 (E), mutant-5 (F), and mutant-19 (G). Results of RT-PCR for the
presence (closed circles) or absence (open circles) of HEV RNA in fecal and serum samples are indicated. IgG anti-HEV antibody is plotted as
the ELISA optical density (A405). The ELISA cutoff value, indicated by a dashed line, is 0.30.
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transfected Huh-7 cells in vitro (5), although the infectivity of
the genotype 1 pHEV5131Ala was not tested in primates. The
results of an in vitro study of a genotype 1 HEV from Graff et
al. (5) and the in vivo results of a genotype 3 HEV presented
in this paper provided convincing evidence that AUG3 is the
authentic ORF3 initiation site and that ORF3 expression is
required for in vivo infectivity.
By analogy with alpha superfamily viruses, the noncoding
junction region should comprise cis-acting elements that are
critical for viral subgenomic RNA synthesis. Tzeng et al. (29)
predicted the subgenomic start site of HEV at nt 5 or 6 up-
stream from AUG3 based upon results with the rubella virus
subgenomic promoter and the conservative nature between the
two viruses. Recently, a continuous 12 nucleotides between
FIG. 4. A conserved double stem-loop RNA secondary structure is predicted by the mfold program in the junction region between ORF1 and
ORF2 of HEV. (A) Genotype 3 HEV and its derived mutants. (B) The other four genotypes of HEV. The four AUGs (AUG1, -2, -3, and 4) in
genotypes 1 through 4 HEV strains and the three AUGs in avian HEV putative genotype 5 are indicated. The contiguous AAC/U triplets are
marked with asterisks. The mutations introduced in mutant-1, -3, and -5 are indicated by italic letters.
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AUG1 and AUG2 were recognized as the cis-acting element in
HEV genotype 1 since mutations in this region eliminated the
production of both ORF2 and ORF3 proteins (4). In an early
study, Tam et al. (23) reported the detection of two sub-
genomic RNA transcripts of approximately 3.7 and 2.0 kb in
HEV-infected liver. Since the N termini of HEV ORF2 and -3
are in close proximity, they could be translated from a single
subgenomic RNA instead of two separate mRNAs, and in-
deed, this was confirmed recently by Graff et al. (5). By using
an artificial in vitro HEV replicon system containing the neo-
mycin resistance gene that was able to synthesize viral RNA,
Graff et al. (5) identified a bicistronic subgenomic mRNA that
encodes both ORF3 and ORF2 (5). The 5 terminus of the
subgenomic mRNA starts at nt 5122 between AUG 2 and
AUG3, suggesting that the first two in-frame AUGs are not
included in the subgenomic RNA, and therefore, they are not
utilized as the initiation sites for ORF3. This in vitro observa-
tion with a genotype 1 HEV is consistent with our in vivo
results with the genotype 3 HEV reported in this study. The
systematic mutagenesis data from this in vivo study also imply
that it is likely all four genotypes of mammalian HEV share the
same characteristics of ORF3 initiation.
Identification of a conserved double stem-loop structure in
the junction regions of all five genotypes of HEV that may be
important for virus replication. RNA secondary structures
often play important roles in viral replication, viral subgenomic
RNA synthesis, and translation efficiency (14, 20). Therefore,
to further understand how mutations in the junction region
may affect virus infectivity, we performed RNA secondary
structure prediction by using the program RNA FOLD (http://
www.bioinfo.rpi.edu/zukerm/rna/) for the junction regions of
the wild-type swine HEV, mutant-1, mutant-3, and mutant-5, all
of which were successfully recovered in pigs but with different
efficiencies.
In wild-type genotype 3 swine HEV, a double stem-loop
structure of approximately 50 nt was identified (Fig. 4A). De-
spite the introduced mutations in the junction region, mu-
tant-1, -3, and -5 still maintain the double stem-loop structure
with subtle differences in the first stem-loop (Fig. 4A). The
cis-acting element between AUG1 and AUG2 in HEV geno-
type 1 comprised 12 continuous nucleotides (4). Aside from
the two AUGs, a conserved 6-nt sequence, AAUAAC, was
found in the loop part of the first stem-loop. The single sub-
stitution in mutant-1 did not alter the nucleotide sequence on
the loop. Accordingly, the infection profile of pigs inoculated
with mutant-1 (Fig. 3D) was indistinguishable from that of the
wild-type virus (Fig. 3A). Compared to that in mutant-1, how-
ever, mutations in mutant-3 and mutant-5 altered the sequence
on the loop from AAUAAC to AACAUG, thus resulting in
less-efficient mutant virus recovery (Fig. 3E and F). Therefore,
it appears that the presence of the exact nucleotides of the
cis-acting element on the loop part of the first stem-loop is
critical for viral infectivity in vivo.
We further compared the predicted secondary structures of
the corresponding junction regions of HEV strains Sar-55 (ge-
notype 1), Mexico (genotype 2), and T1 (genotype 4). All were
shown to fold into a conserved double stem-loop structure
(Fig. 4B). The newly identified start site for the single sub-
genomic RNA of genotype 1 HEV was located in the linking
region between the two stem-loops (5). The structure conser-
vation among four genotypes of HEV supported that the sub-
genomic RNA of HEV genotype 3 starts at the guanine fol-
lowing the four uracils in the linking region (Fig. 4A), which is
the same start site for the human HEV genotype 1 (5).
Interestingly, the junction region of avian HEV putative
genotype 5 (8), which is very divergent in sequence from HEV
genotypes 1 to 4 and consists of more nucleotides in the junc-
tion region, also forms a double stem-loop structure without
the linking nucleotides between the two stem-loops (Fig. 4B).
The contiguous AAC/U triplets also reside on the loop of the
first stem-loop following the UGA stop codon of ORF1, sug-
gesting that this motif may play an important role in viral
replication similar to that in mammalian HEVs. It will now be
interesting to determine whether the first guanine in the sec-
ond stem-loop is the start site for the subgenomic RNA of
avian HEV based upon structure and sequence analogy with
the mammalian HEVs. Future in-depth mutagenesis experi-
ments in this junction region, which are beyond the scope of
this study, are warranted to definitively understand the role of
the stem-loop structures in viral replication.
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